Topical Microbicides: A Promising Approach for Controlling the AIDS Pandemic via Retroviral Zinc Finger Inhibitors

Advances in Pharmacology

Volumn 56, Issue , 2008, Pages 229-256

  Turpin, Jim A ^a   Schito, Marco L ^b   Miller Jenkins, Lisa M ^c   Inman, John K ^a   Appella, Ettore ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; NCP7 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; TOPICAL ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; RETROVIRUS; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG EVALUATION, PRECLINICAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; RETROVIRIDAE; ZINC FINGERS;

EID: 37349074474     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(07)56008-4     Document Type: Review

References (92)

1. Basrur V., Song Y., Mazur S.J., Higashimoto Y., Turpin J.A., Rice W.G., Inman J.K., and Appella E. Inactivation of HIV-1 nucleocapsid protein p7 by pyridinioalkanoyl thioesters. Characterization of reaction products and proposed mechanism of action. J. Biol. Chem. 275 (2000) 14890-14897
2. Berg J.M. Potential metal-binding domains in nucleic acid binding proteins. Science 232 (1986) 485-487
3. Berkowitz R.D., Luban J., and Goff S.P. Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. J. Virol. 67 (1993) 7190-7200
4. Boadi T., Schneider E., Chung S., Tsai L., Gettie A., Ratterree M., Blanchard J., Neurath A.R., and Cheng-Mayer C. Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus. AIDS 19 (2005) 1587-1594
5. 2+ fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA. J. Virol. 77 (2003) 1469-1480
6. Catalone B.J., Kish-Catalone T.M., Budgeon L.R., Neely E.B., Ferguson M., Krebs F.C., Howett M.K., Labib M., Rando R., and Wigdahl B. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 48 (2004) 1837-1847
7. Centers for Disease Control and Prevention. CDC statement on study results of product containing nonoxynol-9. JAMA 284 (2000) 1376
8. Chan D.J. Factors affecting sexual transmission of HIV-1: Current evidence and implications for prevention. Curr. HIV Res. 3 (2005) 223-241
9. Chen X., Chu M., and Giedroc D.P. Spectroscopic characterization of Co(II)-, Ni(II)-, and Cd(II)-substituted wild-type and non-native retroviral-type zinc finger peptides. J. Biol. Inorg. Chem. 5 (2000) 93-101
10. Chertova E.N., Kane B.P., McGrath C., Johnson D.G., Sowder II R.C., Arthur L.O., and Henderson L.E. Probing the topography of HIV-1 nucleocapsid protein with the alkylating agent N-ethylmaleimide. Biochemistry 37 (1998) 17890-17897
11. Cohen M.S., and Pilcher C.D. Amplified HIV transmission and new approaches to HIV prevention. J. Infect. Dis. 191 (2005) 1391-1393
12. Cole A.M. Innate host defense of human vaginal and cervical mucosae. Curr. Top. Microbiol. Immunol. 306 (2006) 199-230
13. Collins K.B., Patterson B.K., Naus G.J., Landers D.V., and Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6 (2000) 475-479
14. Cone R.A., Hoen T., Wong X., Abusuwwa R., Anderson D.J., and Moench T.R. Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect. Dis. 6 (2006) 90
15. Coombs R.W., Speck C.E., Hughes J.P., Lee W., Sampoleo R., Ross S.O., Dragavon J., Peterson G., Hooton T.M., Collier A.C., Corey L., Koutsky L., et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood. J. Infect. Dis. 177 (1998) 320-330
16. Covey S.N. Amino acid sequence homology in gag region of reverse transcribing elements and the coat protein gene of cauliflower mosaic virus. Nucleic Acids Res. 14 (1986) 623-633
17. D'Cruz O.J., and Uckun F.M. Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 10 (2004) 315-336
18. Dawson L., and Yu X.F. The role of nucleocapsid of HIV-1 in virus assembly. Virology 251 (1998) 141-157
19. Dezzutti C.S., James V.N., Ramos A., Sullivan S.T., Siddig A., Bush T.J., Grohskopf L.A., Paxton L., Subbarao S., and Hart C.E. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48 (2004) 3834-3844
20. Dhawan D., and Mayer K.H. Microbicides to prevent HIV transmission: Overcoming obstacles to chemical barrier protection. J. Infect. Dis. 193 (2006) 36-44
21. Doncel G.F., Chandra N., and Fichorova R.N. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 37 Suppl. 3 (2004) S174-S180
22. Foss A.M., Vickerman P.T., Heise L., and Watts C.H. Shifts in condom use following microbicide introduction: Should we be concerned. AIDS 17 (2003) 1227-1237
23. Frank I., and Pope M. The enigma of dendritic cell-immunodeficiency virus interplay. Curr. Mol. Med. 2 (2002) 229-248
24. Garg S., Anderson R.A., Chany II C.J., Waller D.P., Diao X.H., Vermani K., and Zaneveld L.J.D. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 64 (2001) 67-75
25. Gayle H.D. AIDS anniversaries in 2006 mark the time to deliver. Lancet 368 (2006) 425-427
26. Greenhead P., Hayes P., Watts P.S., Laing K.G., Griffin G.E., and Shattock R.J. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74 (2000) 5577-5586
27. Guo J., Wu T., Anderson J., Kane B.F., Johnson D.G., Gorelick R.J., Henderson L.E., and Levin J.G. Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer. J. Virol. 74 (2000) 8980-8988
28. Guo J., Wu T., Kane B.F., Johnson D.G., Henderson L.E., Gorelick R.J., and Levin J.G. Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein. J. Virol. 76 (2002) 4370-4378
29. Gupta P., Mellors J., Kingsley L., Riddler S., Mandaleshwar K.S., Schreiber S., Cronin M., and Rinaldo C.R. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J. Virol. 71 (1997) 6271-6275
30. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5 (2005) 783-792
31. Hargittai M.R., Gorelick R.J., Rouzina I., and Musier-Forsyth K. Mechanistic insights into the kinetics of HIV-1 nucleocapsid protein-facilitated tRNA annealing to the primer binding site. J. Mol. Biol. 337 (2004) 951-968
32. Harouse J.M., Buckner C., Gettie A., Fuller R., Bohm R., Blanchard J., and Cheng-Mayer C. CD8 + T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc. Natl. Acad. Sci. USA 100 (2003) 10977-10982
33. Huang M., Maynard A., Turpin J.A., Graham L., Janini G.M., Covell D.G., and Rice W.G. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J. Med. Chem. 41 (1998) 1371-1381
34. Jenkins L.M.M., Byrd J.C., Hara T., Srivastava P., Mazur S., Stahl S.J., Inman J.K., Appella E., Omichinski J.G., and Legault P. Studies on the inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters. J. Med. Chem. 48 (2005) 2847-2858
35. Jenkins L.M.M., Durell S.R., Maynard A.T., Stahl S.J., Inman J.K., Appella E., Legault P., and Omichinski J.G. Comparison of the specificity of interaction of cellular and viral zinc-binding domains with 2-mercaptobenzamide thioesters. J. Am. Chem. Soc. 128 (2006) 11964-11976
36. Jenkins L.M.M., Hara T., Durell S.R., Hayashi R., Inman J.K., Piquemal J.-P., Gresh N., and Appella E. Specificity of acyl transfer from 2-mercaptobenzamide thioesters to the HIV-1 nucleocapsid protein. J. Am. Chem. Soc. 129 (2007) 11067-11078
37. Karmon E., Potts M., and Getz W.M. Microbicides and HIV: Help or hindrance?. J. Acquir. Immune Defic. Syndr. 34 (2003) 71-75
38. Klasse P.J., Shattock R.J., and Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med. 3 (2006) e351
39. Lapadat-Tapolsky M., De Rocquigny H., Van Gent D., Roques B., Plasterk R., and Darlix J.-L. Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle. Nucleic Acids Res. 21 (1993) 831-839
40. Lard-Whiteford S.L., Matecka D., O'Rear J.J., Yuen I.S., Litterst C., Reichelderfer P., and Microbicides I.W.G.O. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: An update. J. Acquir. Immune Defic. Syndr. 36 (2004) 541-552
41. Lederman M.M., Offord R.E., and Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6 (2006) 371-382
42. Lee B.M., De Guzman R.N., Turner B.G., Tjandra N., and Summers M.F. Dynamical behavior of the HIV-1 nucleocapsid protein. J. Mol. Biol. 279 (1998) 633-649
43. Loo J.A., Holler T.P., Sanchez J., Gogliotti R., Maloney L., and Reily M.D. Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2′-dithiobis[benzamides] and benzisothiazolones. J. Med. Chem. 39 (1996) 4313-4320
44. Lu H., Zhao Q., Wallace G., Liu S., He Y., Shattock R., Neurath A.R., and Jiang S. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retrov. 22 (2006) 411-418
45. Maynard A.T., and Covell D.G. Reactivity of zinc finger cores: Analysis of protein packing and electrostatic screening. J. Am. Chem. Soc. 123 (2001) 1047-1058
46. McGrath C.F., Buckman J.S., Gagliardi T.D., Bosche W.J., Coren L.V., and Gorelick R.J. Human cellular nucleic acid-binding protein Zn2 + fingers support replication of human immunodeficiency virus type 1 when they are substituted in the nucleocapsid protein. J. Virol. 77 (2003) 8524-8531
47. MDS Working Groups. The Microbicide Development Strategy (2006)
48. Miller C.J., and Shattock R.J. Target cells in vaginal HIV transmission. Microbes Infect. 5 (2003) 59-67
49. Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Wietgrefe S., La Franco-Scheuch L., Compton L., Duan L., Shore M.D., Zupancic M., Busch M., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79 (2005) 9217-9227
50. Motakis D., and Parniak M.A. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 1851-1856
51. Neurath A.R., Strick N., Li Y.-Y., and Debnath A.K. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1 (2001) 17
52. Neurath A.R., Strick N., Jiang S., Li Y.-Y., and Debnath A.K. Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of dead-end gp41 six-helix bundles. BMC Infect. Dis. 2 (2002) 6
53. Neurath A.R., Strick N., and Li Y.-Y. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect. Dis. 3 (2003) 27
54. O'Connor T.J., Kinchington D., Kangro H.O., and Jeffries D.J. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int. J. STD AIDS 6 (1995) 267-272
55. Ongradi J., Ceccherini-Nelli L., Pistello M., Specter S., and Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: Clinical implications. AIDS Res. Hum. Retrov. 6 (1990) 1433-1436
56. Patton D.L., Sweeney Y.C., Tsai C.C., and Hillier S.L. Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies. J. Med. Primatol. 33 (2004) 105-108
57. Pereira C.F., and Paridaen J.T.M.L. Anti-HIV drug development-an overview. Curr. Pharm. Des. 10 (2004) 4005-4037
58. Pilcher C.D., Tien H.C., Eron Jr. J.J., Vernazza P.L., Leu S.Y., Stewart P.W., Goh L.E., Cohen M.S., Study Q., and Consortium D.-U.-E.A.H. Brief but efficient: Acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189 (2004) 1785-1792
59. Pope M., and Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med. 9 (2003) 847-852
60. Quayle A.J., Xu C., Mayer K.H., and Anderson D.J. T lymphocytes and macrophages but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J. Infect. Dis 176 (1997) 960-968
61. Ramboarina S., Morellet N., Fournie-Zaluski M.C., and Roques B.P. Structural investigation on the requirement of CCHH zinc finger type in nucleocapsid protein of human immunodeficiency virus 1. Biochemistry 38 (1999) 9600-9607
62. Rice W.G., Hillyer C.D., Harten B., Schaeffer C.A., Dorminy M., Lackey D.A., Kirsten E., Mendeleyev J., Buki K.G., Hakam A., and Kun E. Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. USA 89 (1992) 7703-7707
63. Rice W.G., Schaeffer C.A., Harten B., Villinger F., South T.L., Summers M.F., Henderson L.E., Bess Jr. J.W., Arthur L.O., McDougal J.S., Orloff S.L., Mendeleyev J., et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 361 (1993) 473-475
64. Rice W.G., Turpin J.A., Huang M., Clanton D., Buckheit Jr. R.W., Covell D.G., Wallqvist A., McDonnell N.B., DeGuzman R.N., Summers M.F., Zalkow L., Bader J.P., et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat. Med. 3 (1997) 341-345
65. Ryser H.J.J., Levy E.M., Mandel R., and DiSciullo G.J. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc. Natl. Acad. Sci. USA 91 (1994) 4559-4563
66. Schito M.L., Kennedy P.E., Kowal R., Berger E.A., and Sher A. A human immunodeficiency virus transgenic mouse model for assessing interventions that block microbial-induced proviral expression. J. Infect. Dis. 183 (2001) 1592-1600
67. Schito M.L., Goel A., Song Y., Inman J.K., Fattah R.J., Rice W.G., Turpin J.A., Sher A., and Appella E. In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. AIDS Res. Hum. Retrov. 19 (2003) 91-101
68. Schito M.L., Soloff A.C., Slovitz D., Trichel A., Inman J.K., Appella E., Turpin J.A., and Barratt-Boyes S.M. Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys. Curr. HIV Res. 4 (2006) 379-386
69. Shubsda M.F., Paoletti A.C., Hudson B.S., and Borer P.N. Affinities of packaging domain loops in HIV-1 RNA for the nucleocapsid protein. Biochemistry 41 (2002) 5276-5282
70. Smith R.J., Bodine E.N., Wilson D.P., and Blower S.M. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 19 (2005) 413-421
71. South T.L., Blake P.R., Hare D.R., and Summers M.F. C-terminal retroviral-type zinc finger domain from the HIV-1 nucleocapsid protein is structurally similar to the N-terminal zinc finger domain. Biochemistry 30 (1991) 6342-6349
72. Srivastava P., Schito M., Fattah R.J., Hara T., Hartman T., Buckheit Jr. R.W., Turpin J.A., Inman J.K., and Appella E. Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorgan. Med. Chem. 12 (2004) 6437-6450
73. Stein Z.A. HIV prevention: The need for methods women can use. Am. J. Public Health 80 (1990) 460-462
74. Stone A. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 1 (2002) 977-985
75. Stone A.B. HIV topical microbicides: The current development strategy is fully justified. Am. J. Public Health 94 (2004) 1845-1846
76. Tanchou V., Decimo D., Pechoux C., Lener D., Rogemond V., Berthoux L., Ottmann M., and Darlix J.L. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication. J. Virol. 72 (1998) 4442-4447
77. Tien D., Schnaare R.L., Kang F., Cohl G., McCormick T.J., Moench T.R., Doncel G., Watson K., Buckheit R.W., Lewis M.G., Schwartz J., Douville K., et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retrov. 10 (2005) 845-853
78. Topol I.A., Nemukhin A.V., Dobrogorskaya Y.I., and Burt S.K. Interactions of azodicarbonamide (ADA) species with the model zinc finger site: Theoretical support of the zinc finger domain destruction in the HIV-1 nucleocapsid protein (NCp7) by ADA. J. Phys. Chem. B 105 (2001) 11341-11350
79. Turpin J.A. The next generation of HIV/AIDS drugs: Novel and developmental anti HIV drugs and targets. Expert Rev. Anti. Infect. Ther. 1 (2003) 97-128
80. Turpin J.A., Terpening S.J., Schaeffer C.A., Yu G., Glover C.J., Felsted R.L., Sausville E.A., and Rice W.G. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J. Virol. 70 (1996) 6180-6189
81. Turpin J.A., Song Y., Inman J.K., Huang M., Wallqvist A., Maynard A., Covell D.G., Rice W.G., and Appella E. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. 42 (1999) 67-86
82. UNAIDS. AIDS Epidemic Update: Special Report on HIV/AIDS: December 2006 (2006)
83. van de Wijgert J., Fullem A., Kelly C., Mehendale S., Rugpao S., Kumwenda N., Chirenje Z., Joshi S., Taha T., Padian N., Bollinger R., and Nelson K. Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites. J. Acquir. Immune Defic. Syndr. 26 (2001) 21-27
84. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., and Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005) 99-102
85. Vickerman P., Watts C., Delany S., Alary M., Rees H., and Heise L. The importance of context: Model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex. Transm. Dis. 33 (2006) 397-405
86. Wallace G., Schito M.L., and Appella E. HIV-1 nucleocapsid zinc finger inhibitors (zfi's) impede trans infection in cellular and explant models. Microbicides (2006) April 23-26, 2006: Abstract OA25
87. Wang L.H., Yang X.Y., Zhang X., Mihalic K., Fan Y.X., Xiao W., Howard O.M.Z., Appella E., Maynard A.T., and Farrar W.L. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat. Med. 10 (2004) 40-47
88. Wang L.H., Yang X.Y., Zhang X., An P., Kim H.-J., Huang J., Clarke R., Osborne C.K., Inman J.K., Appella E., and Farrar W.L. Disruption of estrogen receptor DNA binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10 (2006) 487-499
89. Weber J., Desai K., Darbyshire J., and Programme M.D. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2 (2005) 142
90. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., and Boyd M.R. New soluble-formazan assay for HIV-1 cytopathic effects-application to high-flux screening of synthetic and natural-products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81 (1989) 577-586
91. Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K.A., Reimann K.A., Reinhart T.A., Rogan M., Cavert W., Miller C.J., Veazey R.S., Notermans D., et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4 + T cells. Science 286 (1999) 1353-1357
92. Zybarth G., and Carter C. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69 (1995) 3878-3884